Clinical Trial Update: Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial [NA]

View source ↗

Summary

The OPTIMIZE-ILD-2 trial aims to optimize follow-up care for interstitial lung disease and fibrotic ILD, and it is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Connective Tissue Disease-associated Interstitial Lung Disease
• Fibrotic Interstitial Lung Disease
• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease
• Progressive Fibrosing Interstitial Lung Disease

Snippet

Sponsor: Hospital de Granollers | Conditions: Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease | NA | Status: RECRUITING